Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Nov;72(5):1514-1517.
doi: 10.1002/hep.31527.

ImmTAV, a New Immunotherapy Targeting the Source of HBV Infection

Antonio Bertoletti  1   2
Affiliations
Editorial

ImmTAV, a New Immunotherapy Targeting the Source of HBV Infection

Antonio Bertoletti. Hepatology. 2020 Nov.
No abstract available

PubMed Disclaimer

Comment on

  • Immune-Mobilizing Monoclonal T Cell Receptors Mediate Specific and Rapid Elimination of Hepatitis B-Infected Cells.
    Fergusson JR, Wallace Z, Connolly MM, Woon AP, Suckling RJ, Hine DW, Barber C, Bunjobpol W, Choi BS, Crespillo S, Dembek M, Dieckmann N, Donoso J, Godinho LF, Grant T, Howe D, McCully ML, Perot C, Sarkar A, Seifert FU, Singh PK, Stegmann KA, Turner B, Verma A, Walker A, Leonard S, Maini MK, Wiederhold K, Dorrell L, Simmons R, Knox A. Fergusson JR, et al. Hepatology. 2020 Nov;72(5):1528-1540. doi: 10.1002/hep.31503. Hepatology. 2020. PMID: 32770836 Free PMC article.

References

    1. Fanning GC, Zoulim F, Hou J, Bertoletti A. Therapeutic strategies for hepatitis B virus infection: towards a cure. Nat Rev Drug Discov 2019;18:827-844.
    1. Fergusson JR, Wallace Z, Connolly MM, Woon AP, Suckling RJ, Hine DW et al. Immune-mobilising monoclonal T cell receptors mediate specific and rapid elimination of hepatitis B-infected cells. Hepatology 2020;72:1528-540.
    1. Janeway CA. How the immune system works to protect the host from infection: a personal view. Proc Natl Acad Sci USA 2001;98:7461-7468.
    1. Maini MK, Burton AR. Restoring, releasing or replacing adaptive immunity in chronic hepatitis B. Nat Rev Gastro Hepatol 2019;16:662-675.
    1. Gane E, Verdon DJ, Brooks AE, Gaggar A, Nguyen A-H, Subramanian GM, et al. Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: a pilot study. J Hepatol 2019;71:900-907.

Substances